La chaîne d'options affiche les données clés des options sur actions de Dermata Therapeutics à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Dermata Therapeutics..

Dermata Therapeutics (NASDAQ:DRMA) Stock, Chaîne d'Options

Dermata Therapeutics

Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.

Dermata Therapeutics, Inc. - Common Stock

Dermata Therapeutics Inc

News

Press Releases

Dermata's XYNGARI(TM) Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks

Earnings

Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

Dermata Receives Notice of Grant of Australian Patent for Topical Botulinum Toxin Treatment for Hyperhidrosis

Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Dermata Therapeutics Announces Strategic Pivot to Over-the-Counter Skin Care Treatments

Dermata Therapeutics to Present at the Life Sciences Virtual Investor Forum September 18th

Life Science Virtual Investor Forum Agenda Announced for September 18th

Dermata Therapeutics Announces Presentation of Abstract at the European Academy of Dermatology and Venereology Congress 2025

Life Sciences Virtual Investor Forum: Presentations Now Available for Online Viewing

Dermata Announces Acceptance of Patent Application for Next-Generation Acne Treatment by Australian Patent Office

ACUT

DRMA

DRMAW

HMTXF

INNMF

PETV

SIGY

TSXV:HEM

UEEC

Aditxt

Apollomics

Azitra

Bone Biologics

BriaCell Therapeutics

Biodexa Pharmaceuticals plc - American Depositary Shares

Biodexa Pharmaceuticals

Bio Green Med Solution, Inc. - 6% Convertible Preferred Stock

Bio Green Med Solution

Celularity

CERo Therapeutics Holdings, Inc. - Common Stock

CERo Therapeutics Hldgs

Estrella Immunopharma

ETHZilla

GRI Bio

Indaptus Therapeutics, Inc. - Common Stock

Indaptus Therapeutics

Liminatus Pharma

Medicus Pharma

Psyence Biomedical Ltd. - Ordinary Shares

Psyence Biomedical

Qualigen Therapeutics, Inc. - Common Stock

Qualigen Therapeutics

Revelation Biosciences, Inc. - Common Stock

Revelation Biosciences

Revolution Medicines

Scinai Immunotherapeutics Ltd. - American Depositary Shares

Scinai Immunotherapeutics

Shuttle Pharmaceuticals Holdings, Inc. - common stock

Shuttle Pharmaceuticals

Salarius Pharmaceuticals, Inc. - Common Stock

Salarius Pharmaceuticals

Silexion Therapeutics

Alaunos Therapeutics, Inc. - Common Stock

Comments

Dermata Therapeutics

Dermata Therapeutics (DRMA) Options

No option chain data available. Please try again later

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL